EPL Limited delivered a landmark Q4 FY26 performance, reporting 17.6% revenue growth, the highest in five years. The company sustained EBITDA margins above 20% for the seventh consecutive quarter. Driven by a 30% year-on-year surge in the Beauty & Cosmetics segment, EPL continues to shift toward a diversified portfolio while navigating global challenges. The company also announced a strategic merger with Indovida, creating a near $1 billion consumer packaging platform.
Financial Highlights
EPL Limited reported a robust Q4 FY26, characterized by 17.6% revenue growth and 17.2% growth in EBITDA. For the full year, the company achieved 13% revenue growth and a 15% increase in Profit After Tax (PAT). The company’s focus on operational efficiency and pass-through pricing models has helped maintain EBITDA margins at 20.4%, reflecting the resilience of its business model amidst inflationary headwinds.
Strategic Growth in Beauty & Cosmetics
The company’s strategic pivot toward Beauty & Cosmetics has yielded significant results, with the segment recording 30% growth for the year. This segment now accounts for 53% of the company’s Personal Care and Beyond mix, surpassing Oral Care in key markets. Additionally, the Oral Care segment showed a healthy recovery, growing 10% year-on-year, further stabilizing the company’s diversified revenue stream.
Global Operational Performance
Geographic performance remained broad-based during the quarter, with all four major regions delivering double-digit growth. EAP and the Americas led the performance with 25% and 24.1% growth respectively, supported by new customer acquisitions and strong demand in Brazil. Europe grew by 15.5%, while AMESA and India stand-alone recorded growth of 10.4% and 11.5%, respectively.
Sustainability and Future Outlook
EPL continues to lead in sustainability, with sustainable tube formats contributing 38% to total sales. The company also achieved the prestigious EcoVadis Platinum rating, ranking among the top 1% of companies globally for ESG performance. Regarding the proposed merger with Indovida, the management highlighted that the combined entity will form a $1 billion platform, enhancing scale and innovation capabilities across high-growth emerging markets. The merger process is ongoing, with regulatory approvals currently in progress.
Source: BSE
